MicroRNA Signatures as Biomarkers of Colorectal Cancer

Pfütze, Katrin; Luo, Xiaoyu; Burwinkel, Barbara

doi:10.1002/9781118300312.ch19

Cited by 2 publications

(2 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[36][37][38][39] In the present study, our findings revealed that the miR-183 expression in plasma was significantly associated with lymph node metastasis, distant metastasis, pTNM stage, and tumor recurrence. In addition, overexpression of miR-183 in plasma was significantly associated with tumor recurrence and poor survival in CRC patients.…”

Section: Discussionsupporting

confidence: 62%

Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer

Yuan

Zhu

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common malignancies worldwide. The prognosis for this cancer is poor, and the development of novel biomarkers, particularly non-invasive surrogate biomarkers, is urgently needed. Recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in the blood and can serve as useful biomarkers for various types of cancer. In this study, the miR-183 expression levels were found to be significantly overexpressed in plasma samples from CRC patients compared with controls, and the postoperative plasma miR-183 levels were significantly reduced compared with the preoperative levels. The value of the area under the receiver operating characteristic (ROC) curve obtained for miR-183 was 0.829, which was higher than those for carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). High plasma miR-183 expression was significantly associated with lymph node metastasis, distant metastasis, higher pTNM stage (III-IV), and tumor recurrence. CRC patients with elevated miR-183 expression in plasma displayed shorter disease-free survival (DFS) and lower overall survival (OS). More importantly, plasma miR-183 was independently correlated with tumor recurrence and a lower OS. Collectively, our results suggested that the elevated miR-183 in the plasma could be a promising biomarker for predicting the risk of tumor recurrence and poor survival in CRC patients.

show abstract

Section: Discussionsupporting

confidence: 62%

Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer

Yuan

Zhu

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…In colorectal cancer (CRC) many studies have evaluated the feasibility of circulating miRNAs for detecting early stage cancer and also as prognostic/predictive marker (Pfütze et al, 2013). Ng et al achieved this by profiling miRNAs in tissue and plasma, and short-listing miRNAs that were differentially expressed in both.…”

Section: Colorectal Cancermentioning

confidence: 99%

Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures

Madhavan¹,

Ćuk²,

Burwinkel³

et al. 2013

Front. Genet.

Self Cite

103

View full text Add to dashboard Cite

In the recent years, circulating microRNAs (miRNAs) have garnered a lot of attention and interest in the field of disease biomarkers. With characteristics such as high stability, low cost, possibility of repeated sampling and minimal invasiveness, circulating miRNAs are ideal for development into diagnostic tests. There have been many studies reported on the potential of circulating miRNAs as early detection, prognostic, and predictive biomarkers in cancer. Here, we have reviewed the application of plasma and serum miRNAs as biomarkers for cancer focusing on epithelial carcinomas [prostate, breast, lung, colorectal, and gastric cancer (GC)] and hematological malignancies (leukemia and lymphoma). We have also addressed the common challenges that need to be overcome to achieve a successful bench to bedside transition.

show abstract

MicroRNA Signatures as Biomarkers of Colorectal Cancer

Cited by 2 publications

References 88 publications

Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer

Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer

Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures

Contact Info

Product

Resources

About